NuCana plc: NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer
Safety Profile Continues to be Favorable
EDINBURGH, United Kingdom, Jan. 15, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) today announced interim data from the ongoing NuTide:302 study at the ASCO GI Conference, being held virtually January 15-17, 2021.
NuTide:302 is a three-part study investigating NUC-3373, NuCana s targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer. The study is evaluating NUC-3373 s optimal dose and schedule in combination with agents commonly used to treat patients with colorectal cancer and is assessing safety, pharmacokinetics and anti-cancer activity. NUC-3373 has been designed to overcome the main challenges associated with 5-FU and capecitabine, including cancer-resistance mechanisms which limit efficacy, off-target toxicity and administration burdens.
NuCana plc
NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer
NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer
Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy
Safety Profile Continues to be Favorable
EDINBURGH, United Kingdom, Jan. 15, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) today announced interim data from the ongoing NuTide:302 study at the ASCO GI Conference, being held virtually January 15-17, 2021.
NuTide:302 is a three-part study investigating NUC-3373, NuCana’s targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer. The study is evaluating NUC-3373’s optimal dose and schedule in combination with agents commonly used to treat patients with colorectal cancer a
In Washington state, the chances of dying from the virus are also greater for Latino, Black and Indigenous communities. According to the University of Washington’s Institute for Health Metrics and Evaluation, Mexicans, Central Americans and other Latinos in Washington state are six times more likely to die from the virus. In fact, according to the institute, Washington state is one of the riskiest states for Latinos with regard to COVID-19. The chances of dying from the virus is only higher in Washington, D.C.
Dr. Leo Morales, chief diversity officer at the University of Washington School of Medicine, said the reasons why Latinos have a
Renowned experts challenge conventional wisdom across the imaging community
A special issue of the
Journal of the American College of Radiology (JACR), published by Elsevier, challenges conventional wisdom across the imaging community.
This collection of articles, the Provocative Issue, presents extreme opinions on pressing issues confronting radiologists with the deliberate aim of sparking positive dialog and debate that will lead to innovative solutions to improve patient care and imaging-related outcomes.
The issue is guest-edited by:
Caroline Chung, MD, MSc, Director of Advanced Imaging - Strategic Initiative and Director of Imaging Technology and Innovation, Department of Radiation Oncology and Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;
K-State medical director contributes to research on SARS-CoV-2 transmission and quarantine periods
Kyle Goerl, the medical director of Kansas State University s Lafene Health Center, is part of a collaborative team that is providing research-based guidance during the COVID-19 pandemic. The team s latest research contributed to the updated quarantine guidance from the Centers for Disease Control and Prevention.
Goerl is a co-author of the publication Time from Start of Quarantine to SARS-CoV-2 Positive Test Among Quarantined College and University Athletes. The publication appeared in the Morbidity and Mortality Weekly Report from the CDC on Friday, Jan. 8, and involved researchers from multiple organizations and universities.